Skip to main content
. 2023 Jul 24;11:1166308. doi: 10.3389/fcell.2023.1166308

TABLE 2.

m6A in TNF-α-medicated diseases.

Disease/cells m6A Up/Downstream Functional outcome/correlation
Regulator (s) Target (s)
MSCs FTO↓ Nanog↓ Reduce stability
Atherosclerosis METTL14↓ FOXO1↑ Promote transcription
Ankylosing spondylitis METTL14↓ ELMO1↑ Reduce denaturation rate
Enhance directional migration
Intervertebral disc degeneration METTL14↑ MiR-34a-5p↑ Cell cycle arrest and senescence
Lumbar disc herniation WTAP↓ NORAD↓ Facilitates degradation
Diabetic nephropathy METTL14↑ α-klotho↓ Decrease mRNA stability
Osteoarthritis METTL3↓ MMP1↑, MMP3↑ Matrix degradation
MMP13↓, TIMP-1↓, TIMP-2↓
Atherosclerosis ALKBH5↓ Bcl-2↓ Apoptosis
Nephritis METTL3↑ TAB3↑ Enhance stability
Temporomandibular joint osteoarthritis METTL3↓ m6A/Ythdf1/Bcl2 axis↓ Enhance stability (Ythdf1)
YTHDF1↓
Fungal keratitis METTL3↓ PI3K/AKT pathway↑ Unknown
Myocardial inflammation FTO↓ Unknown Unknown
Sepsis YTHDF1↓ YTHDF1/WWP1/NLRP3/caspase-1 axis↑ Promote transcription
RAW 264.7 cells YTHDF2↑ MAP2K4, MAP4K4↑ Stabilization
Osteoclastogenesis YTHDF2↑ NF-κB and MAPK pathway↑ Reduce stabilization

↑: upregulate ↓: downregulate.